Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 4/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9387274 | 0.90 | ACHE (0.50) | ACHEMEN1KMT2ASCN1ASCN2A | |
| SCHEMBL26931611 | 0.86 | GAA (0.46) | ACHEMEN1KMT2ACHRM2OPRM1 | |
| SCHEMBL30728974 | 0.86 | GAA (0.46) | ACHEMEN1KMT2ACHRM2OPRM1 | |
| SCHEMBL15452482 | 0.83 | GAA (0.39) | ACHEMEN1KMT2ACHRM2OPRM1 | |
| SCHEMBL24130978 | 0.82 | ALDH1A1 (0.43) | MEN1KMT2ACHRM2OPRM1ALDH1A1 | |
| SCHEMBL30002131 | 0.82 | ALDH1A1 (0.47) | KMT2ACHRM2OPRM1ALDH1A1 | |
| SCHEMBL2077862 | 0.82 | ALDH1A1 (0.47) | KMT2ACHRM2OPRM1ALDH1A1 | |
| SCHEMBL9391216 | 0.81 | MEN1 (0.48) | ACHEMEN1KMT2ACHRM1CHRM2 | |
| SCHEMBL2643585 | 0.81 | ALDH1A1 (0.50) | KMT2AMAPK1ALDH1A1 | |
| SCHEMBL10848836 | 0.81 | ALDH1A1 (0.50) | KMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2020-01-28 | — | — | US | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2018-07-24 | — | — | US | disclosed |
| US-9505761-B2 | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-11-29 | — | — | US | disclosed |
| US-9505761-B2 | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-11-29 | — | — | US | disclosed |
| US-9505761-B2 | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-11-29 | — | — | US | disclosed |
| US-20160297817-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297817-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2016-10-13 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| WO-2014091268-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2014-06-19 | — | — | WO | disclosed |
| US-20130281359-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281359-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281359-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130225554-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2013-08-29 | — | — | US | disclosed |
| WO-1994000448-A1 | AZACYCLIC AND AZABICYCLIC HYDROXYLAMINES AS MUSCARINIC RECEPTOR AGONISTS | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1994-01-06 | — | — | WO | disclosed |
| US-5086051-A | 1H, 3H-pyrrolo[1,2-c]thiazole-7-carboxamide derivatives and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297817-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | NR0B1, NR0B2, NR2E1 | ACHE 1628/4885MEN1 2361/4885KMT2A 1869/4885 |
| US-10544146-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | ACHE 1833/4885MEN1 2440/4885KMT2A 1744/4885 |
| US-20130281359-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | MRPL21, MGAM, BACE1 | ACHE 136/4885MEN1 1403/4885KMT2A 1328/4885 |
| US-20130225554-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | NR0B1, NR2E1, NR0B2 | ACHE 2156/4885MEN1 2283/4885KMT2A 2047/4885 |
| US-10030019-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NR0B1, NR2E1, NR0B2 | ACHE 1833/4885MEN1 2440/4885KMT2A 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.